Dr John Walter Hayes, MD | |
220 Day Lily Cir, South Kingstown, RI 02879-5498 | |
(401) 783-4723 | |
Not Available |
Full Name | Dr John Walter Hayes |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | 220 Day Lily Cir, South Kingstown, Rhode Island |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154682623 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | MD04531 (Rhode Island) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Walter Hayes, MD 220 Day Lily Cir, South Kingstown, RI 02879-5498 Ph: (401) 783-4723 | Dr John Walter Hayes, MD 220 Day Lily Cir, South Kingstown, RI 02879-5498 Ph: (401) 783-4723 |
News Archive
Consumers can take up aluminium compounds from various sources, including antiperspirants containing aluminium.
Rush Health established a partnership to provide orthopedic and spine surgeries to United Airline employees. Under this arrangement, known as a direct employer contract, United employees and family members across the United States will be able to receive spinal fusion and hip and knee replacement surgeries at Rush University Medical Center in Chicago, and in the future at other Rush Health facilities.
Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).
Anthrax vaccine administered in combination with a short course of antibiotics completely protected nonhuman primates from inhalational anthrax, the most lethal form of the disease, according to scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins.
› Verified 3 days ago